Scholarlink

Background <p>Complement dysregulation is increasingly recognized in Alzheimer’s disease (AD). However, the temporal profile of complement alterations preceding AD onset and their distinction from age-related immune changes remain poorly defined. Clarifying these dynamics could provide insights into AD pathogenesis and identify systemic factors that predict disease onset and progression.</p> Methods <p>We conducted a study involving two cohorts: a longitudinal cohort (<i>n</i> = 235; all cognitively normal at baseline) and a cross-sectional cohort (<i>n</i> = 323; including 53 with AD, 54 with vascular dementia, 51 with Parkinson’s disease dementia, 56 with behavioral variant frontotemporal dementia, and 52 with dementia with Lewy bodies). Plasma levels of 14 complement factors were assessed every 2 years over a 10-year follow-up period in the longitudinal cohort and once in the cross-sectional cohort.</p> Results <p>In the longitudinal cohort, aging was accompanied by gradual reductions in C4, C4b, Factor I, and Properdin and by increases in Factor D. These changes were more pronounced in individuals who subsequently developed AD. Importantly, this pattern of complement alterations was detectable during the preclinical and clinical phases of AD but was not observed in other dementias. In the cross-sectional cohort, the same complement profile was specific to AD and distinguished it from other dementia subtypes.</p> Conclusions <p>The results of this study indicate an AD-specific peripheral complement signature associated with disease development, highlighting complement factors as critical immune mediators that link aging and AD. This signature implicates complement factors as promising systemic markers for early detection and potential therapeutic targeting in preclinical AD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Systemic complement factors in aging, Alzheimer’s disease and other dementias: a longitudinal study over 10 years

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月12日

查看全文
  • Xiaofeng Fu,
  • Huimin Cai,
  • Shuiyue Quan,
  • Weiyun Zhang,
  • Yumei Geng,
  • Qing Tian,
  • Ziye Ren,
  • Yinghao Xu,
  • Chengyu An,
  • Jiaqi Li,
  • Changbiao Chu,
  • Wei Wang,
  • Yana Pang,
  • QianQian Wang,
  • Lu Lu,
  • Qi Wang,
  • Yan Li,
  • Fangyu Li,
  • Shuya Nie,
  • Longfei Jia

摘要

Background

Complement dysregulation is increasingly recognized in Alzheimer’s disease (AD). However, the temporal profile of complement alterations preceding AD onset and their distinction from age-related immune changes remain poorly defined. Clarifying these dynamics could provide insights into AD pathogenesis and identify systemic factors that predict disease onset and progression.

Methods

We conducted a study involving two cohorts: a longitudinal cohort (n = 235; all cognitively normal at baseline) and a cross-sectional cohort (n = 323; including 53 with AD, 54 with vascular dementia, 51 with Parkinson’s disease dementia, 56 with behavioral variant frontotemporal dementia, and 52 with dementia with Lewy bodies). Plasma levels of 14 complement factors were assessed every 2 years over a 10-year follow-up period in the longitudinal cohort and once in the cross-sectional cohort.

Results

In the longitudinal cohort, aging was accompanied by gradual reductions in C4, C4b, Factor I, and Properdin and by increases in Factor D. These changes were more pronounced in individuals who subsequently developed AD. Importantly, this pattern of complement alterations was detectable during the preclinical and clinical phases of AD but was not observed in other dementias. In the cross-sectional cohort, the same complement profile was specific to AD and distinguished it from other dementia subtypes.

Conclusions

The results of this study indicate an AD-specific peripheral complement signature associated with disease development, highlighting complement factors as critical immune mediators that link aging and AD. This signature implicates complement factors as promising systemic markers for early detection and potential therapeutic targeting in preclinical AD.